title: [Purine transport through the blood-brain barrier in hypoxanthine phosphoribosyltransferase deficiency].
abstract: The transfer of purines through the hematoencephalic barrier is poorly understood. Allopurinol inhibits the enzyme xanthine oxidase and increases xanthine and hypoxanthine plasma levels, but it should not increase the cerebrospinal fluid (CSF) levels of these purines owing to the absence of xanthine oxidase in the central nervous system (CNS). In the present study we evaluated the plasma and CSF concentrations of uric acid, hypoxanthine, xanthine and inosine in the baseline state and after 7 days of allopurinol administration (5-10 mg/kg/24 h) in 4 patients with hypoxanthine phosphoribosyltransferase (HPRT) deficiency. The CSF uric acid level was positively correlated with its plasma level (r = 0.93, p less than 0.01). The CSF hypoxanthine and xanthine concentrations were, as a mean, 5 and 2 times higher, respectively, in patients with HPRT deficiency than in 4 control individuals. As hypoxanthine basically comes from adenine nucleotides, while xanthine comes from guanine nucleotides, this finding suggests that in the CNS of patients with HPRT deficiency there is a higher degradation level of adenine nucleotides than of guanine nucleotides. Allopurinol increased plasma concentration of hypoxanthine, xanthine and inosine 4, 10 and 3 times, respectively, in relation to baseline values. In CSF, the mean increase of hypoxanthine and xanthine concentration was 17.5 mumol and 7.7 mumol, respectively, whereas inosine level was unchanged. These results suggest that in HPRT deficiency hypoxanthine and xanthine may be transferred to the brain.
authors.forename: M
authors.initials: M
authors.lastname: López Jiménez
authors.forename: J
authors.initials: J
authors.lastname: García Puig
authors.forename: F
authors.initials: F
authors.lastname: Mateos Antón
authors.forename: T
authors.initials: T
authors.lastname: Ramos Hernández
authors.forename: I
authors.initials: I
authors.lastname: Pascual Castroviejo
authors.forename: J
authors.initials: J
authors.lastname: Ortiz Vázquez
mesh_terms: D000293:Adolescent; D000328:Adult; D000493:Allopurinol / Q000494:pharmacology / Q000627:therapeutic use; D001812:Blood-Brain Barrier; D002648:Child; D002675:Child, Preschool; D006801:Humans; D019271:Hypoxanthine; D007041:Hypoxanthine Phosphoribosyltransferase / Q000172:deficiency*; D007042:Hypoxanthines / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics; D007926:Lesch-Nyhan Syndrome / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D011687:Purines / Q000493:pharmacokinetics*; D019820:Xanthine; D014970:Xanthines / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics
chemical_list: D007042:Hypoxanthines; D011687:Purines; D014970:Xanthines; D019820:Xanthine; D019271:Hypoxanthine; D000493:Allopurinol; D007041:Hypoxanthine Phosphoribosyltransferase
vernacular_title: Transporte de purinas a través de la barrera hematoencefálica en la deficiencia de hipoxantina fosforribosiltransferasa.